<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03243474</url>
  </required_header>
  <id_info>
    <org_study_id>NOMED-AF</org_study_id>
    <nct_id>NCT03243474</nct_id>
  </id_info>
  <brief_title>Non-invasive Monitoring for Early Detection of Atrial Fibrillation</brief_title>
  <official_title>Non-invasive Monitoring for Early Detection of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kardio-Med Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research and Development, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kardio-Med Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to recognize the actual frequency of atrial fibrillation in the&#xD;
      Polish population as well as to determine the independent risk factors for the occurrence of&#xD;
      its clinically symptomatic and asymptomatic forms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AF Survey is a cross-sectional observational study aimed to assess the prevalence and&#xD;
      control of AF and its correlation with CVD risk factors in Poland, based on a representative&#xD;
      sample of adults aged 65+. The main aim of the survey is to assess the prevalence,&#xD;
      detectability and control of AF, heart failure, vascular diseases, arterial hypertension,&#xD;
      stroke, sedentary lifestyle, smoking, lipid disorders, metabolic syndrome, obesity and&#xD;
      diabetes, as well as other factors related to CVD risk such as chronic kidney and liver&#xD;
      diseases, sleeping disorders, depression and selected psychosocial factors.&#xD;
&#xD;
      The assessment of AF prevalence with use of the monitoring system developed and validated&#xD;
      during the first phase of the project, would be composed of a questionnaire, follow-up data&#xD;
      sheet, blood pressure (BP) measurements and a blood sample collection.&#xD;
&#xD;
      The survey consists of three visits to subjects' homes (day: 1; 10+/-4 days and 30+/-4 days)&#xD;
      and one phone contact one year after first visit and would be performed by trained nurses.&#xD;
      The monitoring system would be installed during the first visit for all patients who sign&#xD;
      informed consent form and returned at the third visit one month later. The main questionnaire&#xD;
      will be completed during the first visit, which included detailed questions about present&#xD;
      health status and history of diseases, hospitalizations, and current medications. The&#xD;
      socioeconomic part of the questionnaire included questions concerning the personal and family&#xD;
      situation, economic status, household structure, leisure activities, hobbies, and social&#xD;
      life. During this visit the Geriatric scale of depression evaluation will be given to the&#xD;
      subject to be self-completed, and will be collected at the second visit. BP readings would be&#xD;
      taken three times during each visit to the patient's home. Anthropometric measurements are&#xD;
      taken twice: at visit one and visit three at the end of the ECG monitoring. Blood samples are&#xD;
      taken from subjects at the second visit after 10 to 12-hour fasting. The follow-up data sheet&#xD;
      would be completed at the initial visit and at the follow-up visit twelve months after&#xD;
      inclusion to the survey. The fieldwork is subcontracted to a company specializing in market&#xD;
      research projects for the private and public sectors. The transportation of biological&#xD;
      material to the Central Laboratory has been subcontracted to a company with expertise in&#xD;
      blood sample transport over long distances. Interviewers will be recruited from among&#xD;
      professionally active nurses. Most of them will be social nurses working within local&#xD;
      communities. All nurses participating in the survey will complete special training prepared&#xD;
      for fieldwork executors of the NOMED-AF project.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Actual">March 10, 2019</completion_date>
  <primary_completion_date type="Actual">March 10, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation incidence in general population</measure>
    <time_frame>1 year</time_frame>
    <description>the prevalence of atrial fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart failure incidence</measure>
    <time_frame>1 year</time_frame>
    <description>the prevalence of heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke incidence</measure>
    <time_frame>1 year</time_frame>
    <description>the prevalence of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial hypertension incidence</measure>
    <time_frame>1 year</time_frame>
    <description>the prevalence of arterial hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular diseases incidence</measure>
    <time_frame>1 year</time_frame>
    <description>the prevalence of vascular diseases</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">3014</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>65 - 69 years</arm_group_label>
    <description>The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70 - 74 years</arm_group_label>
    <description>The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75- 79 years</arm_group_label>
    <description>The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 - 84 years</arm_group_label>
    <description>The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>85 - 89 years</arm_group_label>
    <description>The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>≥90 years</arm_group_label>
    <description>The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The survey was designed as a country representative study and was carried out on a sample&#xD;
        of Polish residents aged ≥65 years, divided into six age groups of equal size and gender&#xD;
        proportion (65-69, 70-74, 75-79, 80-84, 85-89 and 90+ years). The planned size of the&#xD;
        research sample was 3,000 subjects (250 subjects for each gender and age group). Research&#xD;
        participants were randomly recruited in clusters, in a stratified, proportional draw&#xD;
        performed in three stages. The reason for overrepresentation of the oldest age groups was&#xD;
        to allow separate analysis of data for older people.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 65 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zbigniew Kalarus, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>KardioMed Silesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Gdańsk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University - Medical College</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomeranian Medical Uniwersity in Szczecin</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comarch Healthcare</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardio-Med Silesia</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Technology and Equipment</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004 Jan 7;43(1):47-52. doi: 10.1016/j.jacc.2003.08.027.</citation>
    <PMID>14715182</PMID>
  </reference>
  <reference>
    <citation>Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, Albert DE, Freedman SB. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol. 2013 Apr 30;165(1):193-4. doi: 10.1016/j.ijcard.2013.01.220. Epub 2013 Mar 7. No abstract available.</citation>
    <PMID>23465249</PMID>
  </reference>
  <reference>
    <citation>Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013 Dec;44(12):3357-64. doi: 10.1161/STROKEAHA.113.001884. Epub 2013 Oct 15.</citation>
    <PMID>24130137</PMID>
  </reference>
  <reference>
    <citation>Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003 Apr 1;107(12):1614-9. doi: 10.1161/01.CIR.0000057981.70380.45. Epub 2003 Mar 24.</citation>
    <PMID>12668495</PMID>
  </reference>
  <reference>
    <citation>Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in the community. Curr Opin Cardiol. 2014 Jan;29(1):28-35. doi: 10.1097/HCO.0000000000000018.</citation>
    <PMID>24281348</PMID>
  </reference>
  <reference>
    <citation>Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace. 2013 Jan;15(1):135-40. doi: 10.1093/europace/eus217. Epub 2012 Jul 11.</citation>
    <PMID>22791299</PMID>
  </reference>
  <reference>
    <citation>Fernandez V, Bejot Y, Zeller M, Hamblin J, Daubail B, Jacquin A, Maza M, Touzery C, Cottin Y, Giroud M. Silent atrial fibrillation after ischemic stroke or transient ischemic attack: interest of continuous ECG monitoring. Eur Neurol. 2014;71(5-6):313-8. doi: 10.1159/000357561. Epub 2014 Mar 26.</citation>
    <PMID>24685765</PMID>
  </reference>
  <reference>
    <citation>Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, Barbieri M, Rizzo MR, Mauro C, Paolisso G. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013 Aug 6;62(6):525-30. doi: 10.1016/j.jacc.2013.02.091. Epub 2013 May 15.</citation>
    <PMID>23684685</PMID>
  </reference>
  <reference>
    <citation>Cha MJ, Park HE, Lee MH, Cho Y, Choi EK, Oh S. Prevalence of and risk factors for silent ischemic stroke in patients with atrial fibrillation as determined by brain magnetic resonance imaging. Am J Cardiol. 2014 Feb 15;113(4):655-61. doi: 10.1016/j.amjcard.2013.11.011. Epub 2013 Nov 23.</citation>
    <PMID>24360776</PMID>
  </reference>
  <reference>
    <citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003 Mar 27;348(13):1215-22. doi: 10.1056/NEJMoa022066.</citation>
    <PMID>12660385</PMID>
  </reference>
  <reference>
    <citation>Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. No abstract available. Erratum In: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.</citation>
    <PMID>22922413</PMID>
  </reference>
  <reference>
    <citation>Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation. 2013 Feb 26;127(8):930-7. doi: 10.1161/CIRCULATIONAHA.112.126656. Epub 2013 Jan 23.</citation>
    <PMID>23343564</PMID>
  </reference>
  <reference>
    <citation>Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014 Mar;16(3):308-19. doi: 10.1093/europace/eut373. Epub 2013 Dec 17. Erratum In: Europace. 2014 Jun;16(6):941.</citation>
    <PMID>24351881</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>March 30, 2019</last_update_submitted>
  <last_update_submitted_qc>March 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kardio-Med Silesia</investigator_affiliation>
    <investigator_full_name>Zbigniew Kalarus</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03243474
org study id: NOMED-AF
nct id: NCT03243474
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The aim of this project is to recognize the actual frequency of atrial fibrillation in the
      Polish population as well as to determine the independent risk factors for the occurrence of
      its clinically symptomatic and asymptomatic forms
The AF Survey is a cross-sectional observational study aimed to assess the prevalence and
      control of AF and its correlation with CVD risk factors in Poland, based on a representative
      sample of adults aged 65+. The main aim of the survey is to assess the prevalence,
      detectability and control of AF, heart failure, vascular diseases, arterial hypertension,
      stroke, sedentary lifestyle, smoking, lipid disorders, metabolic syndrome, obesity and
      diabetes, as well as other factors related to CVD risk such as chronic kidney and liver
      diseases, sleeping disorders, depression and selected psychosocial factors.

      The assessment of AF prevalence with use of the monitoring system developed and validated
      during the first phase of the project, would be composed of a questionnaire, follow-up data
      sheet, blood pressure (BP) measurements and a blood sample collection.

      The survey consists of three visits to subjects' homes (day: 1; 10+/-4 days and 30+/-4 days)
      and one phone contact one year after first visit and would be performed by trained nurses.
      The monitoring system would be installed during the first visit for all patients who sign
      informed consent form and returned at the third visit one month later. The main questionnaire
      will be completed during the first visit, which included detailed questions about present
      health status and history of diseases, hospitalizations, and current medications. The
      socioeconomic part of the questionnaire included questions concerning the personal and family
      situation, economic status, household structure, leisure activities, hobbies, and social
      life. During this visit the Geriatric scale of depression evaluation will be given to the
      subject to be self-completed, and will be collected at the second visit. BP readings would be
      taken three times during each visit to the patient's home. Anthropometric measurements are
      taken twice: at visit one and visit three at the end of the ECG monitoring. Blood samples are
      taken from subjects at the second visit after 10 to 12-hour fasting. The follow-up data sheet
      would be completed at the initial visit and at the follow-up visit twelve months after
      inclusion to the survey. The fieldwork is subcontracted to a company specializing in market
      research projects for the private and public sectors. The transportation of biological
      material to the Central Laboratory has been subcontracted to a company with expertise in
      blood sample transport over long distances. Interviewers will be recruited from among
      professionally active nurses. Most of them will be social nurses working within local
      communities. All nurses participating in the survey will complete special training prepared
      for fieldwork executors of the NOMED-AF project.
observational model: Case-Crossover
time perspective: Prospective
measure: Atrial fibrillation incidence in general population
time frame: 1 year
description: the prevalence of atrial fibrillation
measure: Heart failure incidence
time frame: 1 year
description: the prevalence of heart failure
measure: Stroke incidence
time frame: 1 year
description: the prevalence of stroke
measure: Atrial hypertension incidence
time frame: 1 year
description: the prevalence of arterial hypertension
measure: Vascular diseases incidence
time frame: 1 year
description: the prevalence of vascular diseases
arm group label: 65 - 69 years
description: The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
arm group label: 70 - 74 years
description: The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
arm group label: 75- 79 years
description: The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
arm group label: 80 - 84 years
description: The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
arm group label: 85 - 89 years
description: The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
arm group label: ≥90 years
description: The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 65 Years
maximum age: 110 Years
healthy volunteers: No
last name: Zbigniew Kalarus, Professor
role: Principal Investigator
affiliation: KardioMed Silesia
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Poland
citation: Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004 Jan 7;43(1):47-52. doi: 10.1016/j.jacc.2003.08.027.
PMID: 14715182
citation: Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, Albert DE, Freedman SB. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol. 2013 Apr 30;165(1):193-4. doi: 10.1016/j.ijcard.2013.01.220. Epub 2013 Mar 7. No abstract available.
PMID: 23465249
citation: Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013 Dec;44(12):3357-64. doi: 10.1161/STROKEAHA.113.001884. Epub 2013 Oct 15.
PMID: 24130137
citation: Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003 Apr 1;107(12):1614-9. doi: 10.1161/01.CIR.0000057981.70380.45. Epub 2003 Mar 24.
PMID: 12668495
citation: Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in the community. Curr Opin Cardiol. 2014 Jan;29(1):28-35. doi: 10.1097/HCO.0000000000000018.
PMID: 24281348
citation: Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace. 2013 Jan;15(1):135-40. doi: 10.1093/europace/eus217. Epub 2012 Jul 11.
PMID: 22791299
citation: Fernandez V, Bejot Y, Zeller M, Hamblin J, Daubail B, Jacquin A, Maza M, Touzery C, Cottin Y, Giroud M. Silent atrial fibrillation after ischemic stroke or transient ischemic attack: interest of continuous ECG monitoring. Eur Neurol. 2014;71(5-6):313-8. doi: 10.1159/000357561. Epub 2014 Mar 26.
PMID: 24685765
citation: Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, Barbieri M, Rizzo MR, Mauro C, Paolisso G. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013 Aug 6;62(6):525-30. doi: 10.1016/j.jacc.2013.02.091. Epub 2013 May 15.
PMID: 23684685
citation: Cha MJ, Park HE, Lee MH, Cho Y, Choi EK, Oh S. Prevalence of and risk factors for silent ischemic stroke in patients with atrial fibrillation as determined by brain magnetic resonance imaging. Am J Cardiol. 2014 Feb 15;113(4):655-61. doi: 10.1016/j.amjcard.2013.11.011. Epub 2013 Nov 23.
PMID: 24360776
citation: Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003 Mar 27;348(13):1215-22. doi: 10.1056/NEJMoa022066.
PMID: 12660385
citation: Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. No abstract available. Erratum In: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.
PMID: 22922413
citation: Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation. 2013 Feb 26;127(8):930-7. doi: 10.1161/CIRCULATIONAHA.112.126656. Epub 2013 Jan 23.
PMID: 23343564
citation: Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014 Mar;16(3):308-19. doi: 10.1093/europace/eut373. Epub 2013 Dec 17. Erratum In: Europace. 2014 Jun;16(6):941.
PMID: 24351881
responsible party type: Principal Investigator
investigator affiliation: Kardio-Med Silesia
investigator full name: Zbigniew Kalarus
investigator title: Professor
mesh term: Atrial Fibrillation
sharing ipd: Yes
ipd description: all IPD that underlie results in a publication